ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arrowhead Pharmaceuticals is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has strong momentum, a bullish moving-average setup, supportive options sentiment, and a very favorable analyst backdrop with multiple upgrades and higher price targets. The near-term thesis is driven by upcoming Phase 3 severe hypertriglyceridemia data and regulatory progress for Redemplo, which gives it clear event-driven upside. Based on the data provided, I would buy it now rather than wait for a better entry.
ARWR is in a bullish trend. Price closed at 72.13, above the pivot at 72.183 and near the R1 resistance at 75.388. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. MACD histogram is positive at 0.178, though contracting, suggesting momentum is still bullish but not accelerating. RSI_6 at 64.052 is neutral-to-strong, not overextended yet. Overall, the technical picture supports a constructive long entry, with the stock showing strength after a large yearly run.
["Positive EMA recommendation for Redemplo in familial chylomicronemia syndrome, with a final decision expected by Q2 2026", "Morgan Stanley upgrade to Overweight with a $100 price target", "BofA raised target to $93 and kept Buy", "Upcoming Phase 3 severe hypertriglyceridemia data in Q3, which analysts see as a major value-unlocking event", "Strong retail sentiment turning extremely bullish", "Bullish share-price trend and constructive options positioning"]
["Insiders are selling, with selling activity increasing 162.39% over the last month", "Morgan Stanley and other analysts previously noted that meaningful sales are not expected in 2026", "MACD momentum is positive but contracting, implying the move may be slowing near resistance", "The stock has already had a very large run over the past year, so expectations are elevated"]
In Q1 2026, revenue rose sharply to $264.0M, up 10,461.32% year over year, showing major top-line growth. Gross margin was 100%, indicating highly efficient revenue generation. However, net income fell to $30.8M, down 117.80% YoY, and EPS dropped to 0.22, down 115.83% YoY. The latest quarter season is Q1 2026. Overall, revenue growth is excellent, but profitability metrics were weaker year over year.
Analyst sentiment is strongly positive. Morgan Stanley upgraded ARWR to Overweight from Equal Weight and raised its target to $100 from $78. BofA increased its target to $93 from $81 and maintained a Buy rating. Earlier, BofA had lowered its target to $81 from $84 but kept Buy, and Morgan Stanley had previously held an Equal Weight stance with a lower target. The trend is clearly improving, with more bullish price targets and stronger conviction from Wall Street. Pros: most analysts are Buy or better, average target is $84.18, and recent upgrades point to more upside. Cons: some analysts still view the stock as fairly valued after its strong run, and one earlier Market Perform stance shows not everyone is fully convinced.
